Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs

Calidi Biotherapeutics, Inc. announced that the CIRM has awarded the company a $3.1 million grant to support continued development of the company’s Supernova-1 pre-clinical program through Investigational New Drug application.